PubRank

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Clinical Trial ID NCT00527943

PubWeight™ 21.39‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00527943

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2011 3.20
2 Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008 1.80
3 Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 2012 1.75
4 Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010 1.66
5 Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol 2013 1.51
6 Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. Circ Cardiovasc Interv 2016 1.47
7 The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J 2009 1.16
8 Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2009 1.07
9 The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011 0.93
10 Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor. Vasc Health Risk Manag 2010 0.92
11 Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab 2010 0.86
12 Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circ Cardiovasc Interv 2015 0.79
13 Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc 2015 0.78
14 Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J Am Heart Assoc 2014 0.77
15 Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2022 0.75
16 Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials. J Am Heart Assoc 2016 0.75
17 Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. J Am Heart Assoc 2015 0.75
18 A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass. J Extra Corpor Technol 2010 0.75
19 Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement. Cardiovasc Drugs Ther 2009 0.75
20 Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am Coll Cardiol 2016 0.75
21 Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies. Thromb J 2016 0.75
Next 100